| SC 13D/A | 2024-03-22 | PFIZER INC | Haleon plc | 2,062,236,079 | 22.6% | EDGAR |
| SC 13D/A | 2024-03-19 | PFIZER INC | Haleon plc | 2,955,063,626 | 32.0% | EDGAR |
| SC 13G/A | 2024-03-15 | PFIZER INC | Tourmaline Bio, Inc. | - | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | Akero Therapeutics, Inc. | 2,525,252 | 4.5% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | Cellectis S.A. | 2,786,924 | 3.9% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | AN2 Therapeutics, Inc. | 1,362,499 | 4.6% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | Enliven Therapeutics, Inc. | 389,429 | 1.0% | EDGAR |
| SC 13G/A | 2024-02-14 | PFIZER INC | eFFECTOR Therapeutics, Inc. | 2,243,850 | 3.5% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | PFIZER INC | 506,479,807 | 9.0% | EDGAR |
| SC 13D/A | 2024-01-29 | PFIZER INC | Longboard Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-01-29 | STATE STREET CORP | PFIZER INC | - | 5.1% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | PFIZER INC | 434,748,255 | 7.7% | EDGAR |
| SC 13D/A | 2024-01-19 | PFIZER INC | Haleon plc | 2,955,063,626 | 32.0% | EDGAR |
| SC 13D/A | 2024-01-10 | PFIZER INC | Longboard Pharmaceuticals, Inc. | 3,978,540 | 11.3% | EDGAR |
| SC 13G | 2023-10-27 | PFIZER INC | Tourmaline Bio, Inc. | - | 6.3% | EDGAR |
| SC 13D/A | 2023-10-25 | PFIZER INC | Allogene Therapeutics, Inc. | 22,032,040 | 13.1% | EDGAR |
| SC 13D/A | 2023-10-18 | PFIZER INC | Cerevel Therapeutics Holdings, Inc. | 27,349,211 | 15.4% | EDGAR |
| SC 13D/A | 2023-10-10 | PFIZER INC | Haleon plc | 2,955,063,626 | 32.0% | EDGAR |
| SC 13D/A | 2023-09-11 | PFIZER INC | Haleon plc | 2,955,063,626 | 32.0% | EDGAR |
| SC 13G | 2023-07-10 | PFIZER INC | Caribou Biosciences, Inc. | - | 7.1% | EDGAR |